Vistagen Therapeutics Receives Nasdaq Extension for $1.00 Bid-Price Rule

What Happened
Vistagen Therapeutics, Inc. (VTGN) filed an 8-K on August 5, 2026 reporting that Nasdaq’s Listing Qualifications Staff granted the company a 180‑day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The extension runs through February 1, 2027. The company’s common stock remains listed and fully effective on the Nasdaq Capital Market during the extension.

Key Details

• Nasdaq granted a 180‑day extension (the “Extension Period”) to regain the $1.00 minimum bid price requirement, until February 1, 2027.
• The company previously disclosed (Form 8‑K filed Feb 6, 2026) it failed to meet the minimum bid price for 30 consecutive business days.
• As of the Aug 5, 2026 filing, Vistagen has not yet regained compliance and has informed Nasdaq it intends to cure the deficiency within the Extension Period.
• If compliance is not regained by Feb 1, 2027, Nasdaq will notify the company of delisting and Vistagen may appeal to a Nasdaq Hearing Panel (no assurance an appeal would succeed).

Why It Matters
This update matters because continued failure to meet the $1.00 minimum bid price could lead to delisting from Nasdaq, which can reduce liquidity and may limit investor access to the stock. The extension gives Vistagen additional time to restore the share price above $1.00 and maintain its Nasdaq listing; investors should monitor the company’s stock price and any further updates about compliance or potential appeal outcomes.